(PHVS)
0.00
0.00 (0.00%)
Get all premium features to the best stock analysis tool
0.00
0.00 (0.00%)
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
| Name | Position |
|---|---|
| Dr. Anne A. Lesage Ph.D. | Chief Early Development Officer |
| Dr. Peng Lu M.D., Ph.D. | Chief Medical Officer |
| Dr. Stefan Abele Ph.D. | Chief Technology Operations Officer |
| Maryann Cimino | Director of Corporate Relations |
| Mr. Berndt Axel Edvard Modig CPA, M.B.A. | Co-Founder, CEO & Executive Director |
| Mr. David W. Nassif J.D. | CFO, Chief Legal Officer & Corporate Secretary |
| Mr. Wim Souverijns Ph.D. | Chief Commercial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-01-12 | 6-K | corporate_presentation_j.htm |
| 2025-12-03 | 6-K | d69798d6k.htm |
| 2025-11-12 | 6-K | 6-k_q3_25.htm |
| 2025-09-23 | POSASR | d57322dposasr.htm |
| 2025-09-08 | 6-K | d19198d6k.htm |
| 2025-08-12 | 6-K | phvs-20250630.htm |
| 2025-08-06 | CORRESP | filename1.htm |
| 2025-07-24 | 6-K | d36725d6k.htm |
| 2025-07-10 | 6-K | d17337d6k.htm |
| 2025-06-27 | 6-K | annual_general_meeting_2.htm |
| Ms. Anna Nijdam M.Sc., R.A. |
| Head of Strategic Finance & Principal Accounting Officer |
| Ms. Annick Deschoolmeester | Chief Human Resources Officer |